$USPH
U S PHYSICAL THERAPY INC /NV

2024 Q2 Form 10-Q Financial Statement

#000114036124024976 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $167.2M $155.7M $148.5M
YoY Change 10.37% 4.83% 12.76%
Cost Of Revenue $133.3M $127.3M $117.7M
YoY Change 11.78% 8.18% 11.93%
Gross Profit $33.86M $28.40M $30.86M
YoY Change 5.14% -7.96% 16.06%
Gross Profit Margin 20.25% 18.24% 20.78%
Selling, General & Admin $14.25M $14.09M $13.86M
YoY Change 17.32% 1.63% 19.93%
% of Gross Profit 42.08% 49.59% 44.91%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $4.514M $4.095M $3.788M
YoY Change 17.95% 8.1% -0.94%
% of Gross Profit 13.33% 14.42% 12.28%
Operating Expenses $14.25M $14.09M $13.86M
YoY Change 17.32% 1.63% 19.93%
Operating Profit $19.61M $14.32M $17.00M
YoY Change -2.24% -15.78% 13.08%
Interest Expense -$549.0K -$92.00K -$2.222M
YoY Change -66.22% -95.86% 1333.55%
% of Operating Profit -2.8% -0.64% -13.07%
Other Income/Expense, Net -$4.818M $440.0K -$2.602M
YoY Change 398.24% -116.91% -680.8%
Pretax Income $14.80M $14.76M $14.40M
YoY Change -22.52% 2.5% -7.0%
Income Tax $3.083M $3.139M $2.969M
% Of Pretax Income 20.84% 21.27% 20.62%
Net Earnings $7.506M $8.046M $7.410M
YoY Change -31.26% 8.58% -15.79%
Net Earnings / Revenue 4.49% 5.17% 4.99%
Basic Earnings Per Share $0.47 $0.46 $0.58
Diluted Earnings Per Share $0.47 $0.46 $0.58
COMMON SHARES
Basic Shares Outstanding 15.07M 15.07M 13.03M
Diluted Shares Outstanding 15.07M 15.02M 13.03M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $112.9M $132.3M $32.60M
YoY Change -29.75% 305.74% 34.57%
Cash & Equivalents $112.9M $132.3M $32.61M
Short-Term Investments
Other Short-Term Assets $12.44M $11.72M $10.73M
YoY Change 25.33% 9.22% 165.5%
Inventory
Prepaid Expenses
Receivables $54.66M $55.36M $56.65M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $201.7M $221.1M $117.8M
YoY Change -16.59% 87.74% 22.9%
LONG-TERM ASSETS
Property, Plant & Equipment $26.23M $26.25M $24.64M
YoY Change 5.01% 6.55% -79.19%
Goodwill $549.0M $534.3M $501.3M
YoY Change 8.34% 6.57% 12.99%
Intangibles $123.9M $116.9M $109.0M
YoY Change 15.16% 7.25% 19.06%
Long-Term Investments $12.24M $12.16M $12.16M
YoY Change 0.11% 0.0% -2.11%
Other Assets $4.629M $4.431M $2.593M
YoY Change -1.49% 70.88% 31.49%
Total Long-Term Assets $821.5M $796.1M $750.3M
YoY Change 8.4% 6.1% 12.32%
TOTAL ASSETS
Total Short-Term Assets $201.7M $221.1M $117.8M
Total Long-Term Assets $821.5M $796.1M $750.3M
Total Assets $1.023B $1.017B $868.1M
YoY Change 2.36% 17.18% 13.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.100M $4.866M $4.233M
YoY Change 11.59% 14.95% -34.63%
Accrued Expenses $58.06M $53.75M $45.22M
YoY Change 33.96% 18.86% -11.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.700M $9.222M $7.730M
YoY Change 28.82% 19.3% 867.46%
Total Short-Term Liabilities $107.1M $102.5M $90.83M
YoY Change 24.8% 12.88% 2.04%
LONG-TERM LIABILITIES
Long-Term Debt $135.7M $136.7M $182.7M
YoY Change -5.41% -25.14% 49.58%
Other Long-Term Liabilities $5.507M $2.988M $13.87M
YoY Change -56.91% -78.46% -81.85%
Total Long-Term Liabilities $141.2M $139.7M $196.6M
YoY Change -9.62% -28.91% 60.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $107.1M $102.5M $90.83M
Total Long-Term Liabilities $141.2M $139.7M $196.6M
Total Liabilities $353.2M $345.3M $384.4M
YoY Change 2.64% -10.17% -16.96%
SHAREHOLDERS EQUITY
Retained Earnings $226.5M $223.6M $234.8M
YoY Change -4.71% -4.77%
Common Stock $172.0K $172.0K $152.0K
YoY Change 0.0% 13.16%
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M $31.63M $31.63M
YoY Change 0.0% 0.0%
Treasury Stock Shares $2.215M
Shareholders Equity $484.6M $479.8M $318.1M
YoY Change
Total Liabilities & Shareholders Equity $1.023B $1.017B $868.1M
YoY Change 2.36% 17.18% 13.65%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income $7.506M $8.046M $7.410M
YoY Change -31.26% 8.58% -15.79%
Depreciation, Depletion And Amortization $4.514M $4.095M $3.788M
YoY Change 17.95% 8.1% -0.94%
Cash From Operating Activities $28.99M $4.419M $11.35M
YoY Change 5.69% -61.06% -2.58%
INVESTING ACTIVITIES
Capital Expenditures $2.336M $1.838M $2.059M
YoY Change -5.19% -10.73% -181.45%
Acquisitions $15.97M $5.796M
YoY Change 175.55% -48.44%
Other Investing Activities -$25.96M -$88.00K -$10.62M
YoY Change 474.86% -99.17% -20.83%
Cash From Investing Activities -$28.29M -$20.46M -$12.68M
YoY Change 305.37% 61.38% -20.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $938.0K $938.0K
YoY Change 0.0%
Cash From Financing Activities -20.08M -4.490M 2.343M
YoY Change -118.65% -291.63% -5548.84%
NET CHANGE
Cash From Operating Activities 28.99M 4.419M 11.35M
Cash From Investing Activities -28.29M -20.46M -12.68M
Cash From Financing Activities -20.08M -4.490M 2.343M
Net Change In Cash -19.38M -20.54M 1.011M
YoY Change -115.12% -2131.16% -123.31%
FREE CASH FLOW
Cash From Operating Activities $28.99M $4.419M $11.35M
Capital Expenditures $2.336M $1.838M $2.059M
Free Cash Flow $26.66M $2.581M $9.290M
YoY Change 6.77% -72.22% -34.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2936000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17282822
CY2023Q1 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity
611000
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000885978
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
155675000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148509000
CY2024Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
93731000
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
86040000
CY2024Q1 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
31916000
CY2023Q1 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
30100000
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1627000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1512000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
127274000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
117652000
CY2024Q1 us-gaap Gross Profit
GrossProfit
28401000
CY2023Q1 us-gaap Gross Profit
GrossProfit
30857000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14085000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13859000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
14316000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
16998000
CY2024Q1 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
1968000
CY2023Q1 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
2560000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1543000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
64000
CY2024Q1 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
612000
CY2023Q1 usph Change In Fair Value Of Contingent Consideration Liability
ChangeInFairValueOfContingentConsiderationLiability
-698000
CY2024Q1 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
-80000
CY2023Q1 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
-149000
CY2024Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
271000
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
274000
CY2024Q1 usph Relief Funds
ReliefFunds
0
CY2023Q1 usph Relief Funds
ReliefFunds
467000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
62000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
440000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2602000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14756000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14396000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3139000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2969000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
11617000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
11427000
CY2024Q1 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
2227000
CY2023Q1 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
2720000
CY2024Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1344000
CY2023Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1297000
CY2024Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3571000
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
4017000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
8046000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
7410000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15017000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15017000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13025000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13025000
CY2024Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.44
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.43
CY2024Q1 us-gaap Profit Loss
ProfitLoss
11617000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
11427000
CY2024Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
-1781000
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
1817000
CY2024Q1 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
455000
CY2023Q1 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-464000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
12943000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
10074000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
3571000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
4017000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9372000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6057000
CY2024Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
0
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
19000
CY2024Q1 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity
0
CY2024Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
6630000
CY2023Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
5617000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
477410000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
8046000
CY2024Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1344000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2024Q1 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
1439000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1997000
CY2024Q1 usph Sale Of Non Controlling Interest Net Of Tax And Purchases
SaleOfNonControllingInterestNetOfTaxAndPurchases
198000
CY2024Q1 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
383000
CY2024Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
6630000
CY2024Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1060000
CY2024Q1 usph Deferred Taxes Related To Redeemable Non Controlling Interest Temporary Equity
DeferredTaxesRelatedToRedeemableNonControllingInterestTemporaryEquity
-175000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1326000
CY2024Q1 usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
600000
CY2024Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
-1000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
481233000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
317053000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
7410000
CY2023Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1297000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2023Q1 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
119000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1806000
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
5617000
CY2023Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1139000
CY2023Q1 usph Deferred Taxes Related To Redeemable Non Controlling Interest Temporary Equity
DeferredTaxesRelatedToRedeemableNonControllingInterestTemporaryEquity
137000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1353000
CY2023Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
1000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
319476000
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2024Q1 usph Number Of Clinics Operated
NumberOfClinicsOperated
679
CY2024Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
42
CY2024Q1 usph Number Of Clinics Operated
NumberOfClinicsOperated
679
CY2024Q1 usph Number Of Physical Therapy Practices Managed
NumberOfPhysicalTherapyPracticesManaged
41
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2024Q1 usph Number Of Regions
NumberOfRegions
6
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q1 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
5500000
CY2024Q1 us-gaap Unrealized Gain Loss On Interest Rate Cash Flow Hedges Pretax Accumulated Other Comprehensive Income Loss
UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss
1300000
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2024Q1 us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
CY2023Q1 us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
80000
CY2024Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1000000
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
1000000
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
10800000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
12500000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
8046000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
7410000
CY2024Q1 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-1439000
CY2023Q1 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
119000
CY2024Q1 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-368000
CY2023Q1 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
30000
CY2024Q1 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
6975000
CY2023Q1 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
7499000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.58
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15017000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15017000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13025000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13025000
CY2023Q4 us-gaap Goodwill
Goodwill
509571000
CY2022Q4 us-gaap Goodwill
Goodwill
494101000
CY2024Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
25056000
CY2023 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
28083000
CY2024Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-356000
CY2023 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
3187000
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
15800000
CY2024Q1 us-gaap Goodwill
Goodwill
534271000
CY2023Q4 us-gaap Goodwill
Goodwill
509571000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
15800000
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
156877000
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
39989000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
116888000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
147690000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
38008000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
109682000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5076000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4443000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53749000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1981000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1817000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17104000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25641000
CY2024Q1 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
7905000
CY2023Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
8847000
CY2024Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
6630000
CY2023Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
0
CY2024Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2658000
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2301000
CY2024Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
1915000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1006000
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
10074000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
12285000
CY2024Q1 usph Other Property Taxes Payable
OtherPropertyTaxesPayable
386000
CY2023Q4 usph Other Property Taxes Payable
OtherPropertyTaxesPayable
355000
CY2024Q1 usph Purchase Of Redeemable Non Controlling Interests Current
PurchaseOfRedeemableNonControllingInterestsCurrent
1495000
CY2023Q4 usph Purchase Of Redeemable Non Controlling Interests Current
PurchaseOfRedeemableNonControllingInterestsCurrent
0
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
255000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
235000
CY2024Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
251000
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
231000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
55344000
CY2024Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
147321000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1350000
CY2024Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
145971000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
148150000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1468000
CY2023Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
146682000
CY2024Q1 usph Debt Instrument Face Amount Current
DebtInstrumentFaceAmountCurrent
9642000
CY2024Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
420000
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
9222000
CY2023Q4 usph Debt Instrument Face Amount Current
DebtInstrumentFaceAmountCurrent
8111000
CY2023Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
420000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7691000
CY2024Q1 usph Debt Instrument Face Amount Noncurrent
DebtInstrumentFaceAmountNoncurrent
137679000
CY2024Q1 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
930000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
136749000
CY2023Q4 usph Debt Instrument Face Amount Noncurrent
DebtInstrumentFaceAmountNoncurrent
140039000
CY2023Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1048000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
138991000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
11617000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
11427000
CY2024Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
-1781000
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification Before Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
1817000
CY2024Q1 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
455000
CY2023Q1 usph Other Comprehensive Income Loss Tax Expense Benefit At Federal And State Statutory Income Tax Rate
OtherComprehensiveIncomeLossTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-464000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
12943000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
10074000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
3571000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
4017000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9372000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6057000
CY2024Q1 usph Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16512000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
119633000
CY2024Q1 us-gaap Interest Rate Cash Flow Hedge Asset At Fair Value
InterestRateCashFlowHedgeAssetAtFairValue
5517000
CY2023Q1 us-gaap Interest Rate Cash Flow Hedge Asset At Fair Value
InterestRateCashFlowHedgeAssetAtFairValue
3561000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
9953000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
9365000
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
265000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
274000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
2369000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
2132000
CY2024Q1 us-gaap Lease Cost
LeaseCost
12587000
CY2023Q1 us-gaap Lease Cost
LeaseCost
11771000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
10338000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
9646000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7727000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6281000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
29610000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
32448000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
24492000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16571000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9254000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
110379000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.031
CY2024Q1 usph Percentage Of General Partnership Interest Owned
PercentageOfGeneralPartnershipInterestOwned
0.01
CY2024Q1 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2
CY2023 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
8
CY2024Q1 us-gaap Revenues
Revenues
155675000
CY2023Q1 us-gaap Revenues
Revenues
148509000
CY2024Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
93731000
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
86040000
CY2024Q1 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
31916000
CY2023Q1 usph Rent Supplies Contract Labor And Other
RentSuppliesContractLaborAndOther
30100000
CY2024Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1627000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1512000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
127274000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
117652000
CY2024Q1 us-gaap Gross Profit
GrossProfit
28401000
CY2023Q1 us-gaap Gross Profit
GrossProfit
30857000
CY2024Q1 us-gaap Assets
Assets
1017256000
CY2023Q1 us-gaap Assets
Assets
868127000
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001140361-24-024976-index-headers.html Edgar Link pending
0001140361-24-024976-index.html Edgar Link pending
0001140361-24-024976.txt Edgar Link pending
0001140361-24-024976-xbrl.zip Edgar Link pending
ef20026319_10q.htm Edgar Link pending
ef20026319_ex31-1.htm Edgar Link pending
ef20026319_ex31-2.htm Edgar Link pending
ef20026319_ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
ef20026319_10q_htm.xml Edgar Link completed
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-20240331.xsd Edgar Link pending
usph-20240331_cal.xml Edgar Link unprocessable
usph-20240331_def.xml Edgar Link unprocessable
usph-20240331_lab.xml Edgar Link unprocessable
usph-20240331_pre.xml Edgar Link unprocessable